Remove Insulin Remove Packaging Remove Trials
article thumbnail

Roche debuts smart glucose monitor for hospital use

pharmaphorum

.” The Android-powered device can run certified third-party software, initially shipping with a handful of apps including Glytec’s Glucommander insulin-dosing software under the terms of a deal announced today.

Insulin 128
article thumbnail

MIOTIFY platform for digital health products clears AZ road test

pharmaphorum

UK company MIOTIFY has developed a web-based software platform that product teams can use to configure medical algorithms quickly, create code packages to harness them and generate supporting documentation – all in a format that is designed to meet regulatory requirements for software as a medical device (SaMD). Sheena Macpherson.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GLP1 Receptor Agonist Market: Current Landscape, Growth Opportunities and Future Market Outlook

Roots Analysis

per package in the US. Growing Interclass Drug Competition: The diabetes treatment market is highly competitive, comprising of various alternative therapies (including oral anti-diabetics, insulin, and other injectable medications); notably, the introduction of biosimilars is likely to impact the dynamics of this market.

article thumbnail

Tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes

The Pharma Data

SURPASS-2 was a 40-week, randomized, open-label trial comparing the efficacy and safety of tirzepatide to semaglutide as an add-on to metformin in adults with type 2 diabetes. Lilly intends to submit the full registration package to regulatory authorities by the end of 2021. The trial randomized 1,879 study participants across the U.S.,

article thumbnail

Tirzepatide’s superior A1C and body weight reductions versus placebo in adults with type 2 diabetes

The Pharma Data

Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of treatment in Eli Lilly and Company’s (NYSE: LLY) SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety of tirzepatide compared to placebo. Source link: [link].

article thumbnail

Pharma Marketing Network - Untitled Article

Pharma Marketing Network

Don ( PMN): This is really interesting too and that is the one that we’ve spoken about earlier in previous conversations was the aerosolized insulin? Robin (Guest): Eliminating the needle and it’s a smart connected device and so you can track the insulin uses really really easily. Robin (Guest): Yup. Don ( PMN): Wow.

Insulin 52
article thumbnail

Pharma Marketing Network - Untitled Article

Pharma Marketing Network

Don ( PMN): This is really interesting too and that is the one that we’ve spoken about earlier in previous conversations was the aerosolized insulin? Robin (Guest): Eliminating the needle and it’s a smart connected device and so you can track the insulin uses really really easily. Robin (Guest): Yup. Don ( PMN): Wow.

Insulin 52